摘要:
The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 2, 7, 22, 25, 33, 35, 37, 38, 42, 47, 64, 69 or 77, 82, 97, 100, 108, 110, 112, 113, 117, 122, 139, 151, 158, 160, 172, 182, 184, 187, 188, 194.
摘要翻译:本发明涉及基于由SEQ ID No.2,7,22,25,33所示的本发明基因观察到的差异表达,在成骨领域中新治疗化合物的诊断,治疗和筛选方法 ,35,37,38,42,47,64,69或77,82,97,100,108,110,112,113,117,122,139,151,158,160,172,182,184,187 ,188,194。
摘要:
The present invention relates to a highly accurate and reproducible mathematically-based methodology for quantifying the levels of differential gene expression from microassay protocols. Specifically, the present invention provides a simple deductive approach, grounded in a Bayesian framework, to circumvent the heuristic-based limitation of previous methodologies. Rather than seeking a point-estimate of the fold-change of the level of gene expression, the present invention utilizes the derivation of mathematical formula to determine the a posteriori distribution of all the fold-changes of differential gene expression which may be inferred from the given measurements. From this a posteriori distribution the following information may be obtained: (i) an estimator for the fold-change of the level of gene expression; (ii) confidence limits for the fold-change, at any given confidence level; and (iii) a P-value for assessing the statistical significance of change. The present invention also possesses the advantage that fold-change estimates and confidence limits may even be assigned to signal pairs where both signals are zero or negative, without resorting to heuristic thresholds.